Mattias Carlsten

List of Publications by Year
in descending order

54 papers	2,962 citations	218592 26 h-index	189801 50 g-index
55 all docs	55 docs citations	55 times ranked	4301 citing authors

#	Article	IF	Citations
1	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 655-666.	1.4	1
2	A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells <i>in vitro</i> and <i>in vivo</i>. Haematologica, 2022, 107, 1786-1795.	1.7	5
3	Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cellâ€“mediated tumor responses. Blood Advances, 2022, 6, 3352-3366.	2.5	30
4	Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. British Journal of Haematology, 2021, 193, 951-960.	1.2	8
5	The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. BMC Cancer, 2021, 21, 500.	1.1	5
6	Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications. Molecular Imaging and Biology, 2021, 23, 952-962.	1.3	4
7	LIRâ€1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibodyâ€dependent cellular cytotoxicity. Clinical and Translational Immunology, 2021, 10, e1346.	1.7	8
8	A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo. Blood, 2021, 138, 2861-2861.	0.6	1
9	Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 621225.	2.2	34
10	CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. Methods in Molecular Biology, 2020, 2121, 213-239.	0.4	13
11	Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Frontiers in Immunology, 2019, 10, 2357.	2.2	99
12	Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness. Frontiers in Immunology, 2019, 10, 2164.	2.2	23
13	Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. OncoImmunology, 2019, 8, e1534664.	2.1	25
14	Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X. Frontiers in Immunology, 2019, 10, 1262.	2.2	47
15	The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994â€“2016. Experimental Hematology and Oncology, 2019, 8, 7.	2.0	14
16	Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer. Frontiers in Immunology, 2019, 10, 1047.	2.2	77
17	Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor. Blood, 2019, 134, 138-138.	0.6	1
18	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clinical Cancer Research, 2018, 24, 1834-1844.	3.2	136

#	Article	IF	Citations
19	Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. PLoS ONE, 2018, 13, e0202651.	1.1	11
20	Natural killer cell-mediated immunosurveillance of human cancer. Seminars in Immunology, 2017, 31, 20-29.	2.7	240
21	Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19. Frontiers in Immunology, 2016, 7, 105.	2.2	90
22	mRNA Transfection to Improve NK Cell Homing to Tumors. Methods in Molecular Biology, 2016, 1441, 231-240.	0.4	16
23	Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. Clinical Cancer Research, 2016, 22, 5211-5222.	3.2	137
24	A Naive NK Cell Repertoire in the Circulation of Haploidentical Stem Cell Donors Pre Mobilization Predicts Rejection of Cord Myeloid Cells in Patients Undergoing Combined Haploidentical and Unrelated Cord Blood HSCT. Blood, 2016, 128, 2199-2199.	0.6	1
25	Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Frontiers in Immunology, 2015, 6, 266.	2.2	184
26	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nature Reviews Drug Discovery, 2015, 14, 487-498.	21.5	203
27	Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells. Journal of Immunology, 2015, 194, 4518-4527.	0.4	81
28	Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma. Blood, 2015, 126, 4244-4244.	0.6	10
29	mRNA Transfection of NK Cells with Gain-of-Function CXCR4 As a Novel Method to Enhance the Homing of Adoptively Transferred NK Cells to the Bone Marrow for the Treatment of Hematological Malignancies. Blood, 2015, 126, 3089-3089.	0.6	0
30	ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment. Blood, 2015, 126, 4296-4296.	0.6	0
31	Ex Vivo Expanded NK Cells Mediate Highly Efficient and Rapid Killing of Ewing Sarcoma Cells Through Degranulation with Tumor Cytotoxicity Controlled by the NKG2D, DNAM-1, and NKp30 NK Receptors. Blood, 2015, 126, 1894-1894.	0.6	0
32	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395.	3.7	106
33	A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica, 2014, 99, e81-e83.	1.7	112
34	A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia. Blood, 2014, 124, 1047-1047.	0.6	5
35	Clinical-Grade mRNA Electroporation of NK Cells: A Novel and Highly Efficient Method to Genetically Reprogram Human NK Cells for Cancer Immunotherapy. Blood, 2014, 124, 2153-2153.	0.6	7
36	Early biomarkers of response to carfilzomib in multiple myeloma (MM): Modulation of CXCR4 and induction of autophagy.. Journal of Clinical Oncology, 2014, 32, e19572-e19572.	0.8	2

#	Article	IF	Citations
37	Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia. Blood, 2014, 124, 1120-1120.	0.6	0
38	Doxorubicin sensitizes human tumor cells to NK cellâ€•and Tâ€•cellâ€•mediated killing by augmented TRAIL receptor signaling. International Journal of Cancer, 2013, 133, 1643-1652.	2.3	54
39	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. Blood, 2012, 120, 3283-3283.	0.6	2
40	Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells. Journal of Immunology, 2011, 187, 3546-3554.	0.4	40
41	A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity. Blood, 2011, 118, 1001-1001.	0.6	3
42	Optimizing Lentiviral Transduction of Human Natural Killer Cells. Blood, 2011, 118, 4714-4714.	0.6	37
43	A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma. Blood, 2011, 118, 2944-2944.	0.6	1
44	Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia, 2010, 24, 1607-1616.	3.3	85
45	Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells. Journal of Immunology, 2009, 183, 4921-4930.	0.4	227
46	Natural killer cellâ€•mediated lysis of freshly isolated human tumor cells. International Journal of Cancer, 2009, 124, 757-762.	2.3	35
47	Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides. Biochemical and Biophysical Research Communications, 2009, 390, 1272-1277.	1.0	24
48	NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 1541-1552.	2.0	74
49	Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype. Journal of Immunology, 2008, 181, 6010-6019.	0.4	99
50	DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells. Cancer Research, 2007, 67, 1317-1325.	0.4	198
51	Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Research, 2006, 66, 6387-6394.	0.4	58
52	IFN-Î³ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. Journal of Clinical Investigation, 2002, 110, 1515-1523.	3.9	135
53	IFN-Î³ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. Journal of Clinical Investigation, 2002, 110, 1515-1523.	3.9	75
54	The Core Promoter of Human Thioredoxin Reductase 1. Journal of Biological Chemistry, 2001, 276, 30542-30551.	1.6	79